Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 4
2006 3
2007 5
2008 3
2009 10
2010 14
2011 6
2012 11
2013 11
2014 17
2015 15
2016 15
2017 5
2018 11
2019 7
2020 6
2021 14
2022 12
2023 4

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Wakelee H, et al. N Engl J Med. 2023 Jun 3. doi: 10.1056/NEJMoa2302983. Online ahead of print. N Engl J Med. 2023. PMID: 37272513
BACKGROUND: Among patients with resectable early-stage non-small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit beyond either approach alone. ...Participants with …
BACKGROUND: Among patients with resectable early-stage non-small-cell lung cancer (NSCLC), a perioperative approach that inclu …
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.
Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, Sacher AG, Takahashi T, Ramalingam SS, Dooms C, Kim DW, Addeo A, Desai J, Schuler M, Tomasini P, Hong DS, Lito P, Tran Q, Jones S, Anderson A, Hindoyan A, Snyder W, Skoulidis F, Li BT. Dy GK, et al. J Clin Oncol. 2023 Apr 25:JCO2202524. doi: 10.1200/JCO.22.02524. Online ahead of print. J Clin Oncol. 2023. PMID: 37098232
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updat …
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the pri …
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
de Braud F, Dooms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D, Rutkowski P, Wolf J, Ascierto PA, Gil-Bazo I, Kato S, Wolodarski M, McKean M, Muñoz Couselo E, Sebastian M, Santoro A, Cooke V, Manganelli L, Wan K, Gaur A, Kim J, Caponigro G, Couillebault XM, Evans H, Campbell CD, Basu S, Moschetta M, Daud A. de Braud F, et al. J Clin Oncol. 2023 May 10;41(14):2651-2660. doi: 10.1200/JCO.22.02018. Epub 2023 Mar 22. J Clin Oncol. 2023. PMID: 36947734 Clinical Trial.
PURPOSE: No approved targeted therapy for the treatment of patients with neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS)-mutant melanoma is currently available. PATIENTS AND METHODS: In this phase Ib escalation/expansion study (ClinicalTrials.gov identifier: …
PURPOSE: No approved targeted therapy for the treatment of patients with neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS)-mutant mela …
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L; CodeBreaK 200 Investigators. de Langen AJ, et al. Lancet. 2023 Mar 4;401(10378):733-746. doi: 10.1016/S0140-6736(23)00221-0. Epub 2023 Feb 7. Lancet. 2023. PMID: 36764316 Clinical Trial.
BACKGROUND: Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRAS(G12C). We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRAS(G12C) mu …
BACKGROUND: Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRAS(G12C). We compared the efficacy and safety of …
[68Ga]Ga-DOTATATE-avid tumor volume, uptake and inflammation-based index correlate with survival in neuroendocrine tumor patients treated with [177Lu]Lu-DOTATATE PRRT.
Pauwels E, Dekervel J, Verslype C, Clement PM, Dooms C, Baete K, Goffin K, Jentjens S, Van Laere K, Van Cutsem E, Deroose CM. Pauwels E, et al. Am J Nucl Med Mol Imaging. 2022 Oct 15;12(5):152-162. eCollection 2022. Am J Nucl Med Mol Imaging. 2022. PMID: 36419585 Free PMC article.
The previously identified SUV(mean) cut-off of 13.7 for better survival could not be applied to this patient cohort. Instead, a more optimal cut-off could be identified: an SUV(mean) lower or equal than 11.2 was associated with worse overall sur …
The previously identified SUV(mean) cut-off of 13.7 for better survival could not be applied to this patient cohort. In …
Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis.
Franken A, Van Mol P, Vanmassenhove S, Donders E, Schepers R, Van Brussel T, Dooms C, Yserbyt J, De Crem N, Testelmans D, De Wever W, Nackaerts K, Vansteenkiste J, Vos R, Humblet-Baron S, Lambrechts D, Wauters E. Franken A, et al. J Immunother Cancer. 2022 Sep;10(9):e005323. doi: 10.1136/jitc-2022-005323. J Immunother Cancer. 2022. PMID: 36171010 Free PMC article.
The CD4+ T-cell compartment showed an increase of pathogenic T-helper 17.1 cells, characterized by high co-expression of TBX21 (encoding T-bet) and RORC (ROR-gamma), IFN-G (IFN-gamma), IL-17A, CSF2 (GM-CSF), and cytotoxic …
The CD4+ T-cell compartment showed an increase of pathogenic T-helper 17.1 cells, characterized by high …
The impact of endoscopic lung volume reduction on physical activity coaching in patients with severe emphysema.
Blondeel A, Demeyer H, Ceulemans LJ, Coolen J, Everaerts S, Geysen H, Verleden GM, Van Raemdonck D, Dooms C, Troosters T, Janssens W. Blondeel A, et al. ERJ Open Res. 2022 Jun 27;8(2):00150-2022. doi: 10.1183/23120541.00150-2022. eCollection 2022 Apr. ERJ Open Res. 2022. PMID: 35769416 Free PMC article.
The primary end-point of this research question was the change in daily step count from baseline to 6 months follow-up compared between the ELVR and no-ELVR cohort. ...Patients in the ELVR group tended to experience less difficulty with PA compared …
The primary end-point of this research question was the change in daily step count from baseline to 6 months follow-up comp …
Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets.
Che H, Jatsenko T, Lenaerts L, Dehaspe L, Vancoillie L, Brison N, Parijs I, Van Den Bogaert K, Fischerova D, Heremans R, Landolfo C, Testa AC, Vanderstichele A, Liekens L, Pomella V, Wozniak A, Dooms C, Wauters E, Hatse S, Punie K, Neven P, Wildiers H, Tejpar S, Lambrechts D, Coosemans A, Timmerman D, Vandenberghe P, Amant F, Vermeesch JR. Che H, et al. Clin Chem. 2022 Sep 1;68(9):1164-1176. doi: 10.1093/clinchem/hvac095. Clin Chem. 2022. PMID: 35769009
BACKGROUND: Cell-free DNA (cfDNA) analysis holds great promise for non-invasive cancer screening, diagnosis, and monitoring. We hypothesized that mining the patterns of cfDNA shallow whole-genome sequencing datasets from patients with cancer …
BACKGROUND: Cell-free DNA (cfDNA) analysis holds great promise for non-invasive cancer screening, diagnosis, and monito …
Lung Aeration in COVID-19 Pneumonia by Ultrasonography and Computed Tomography.
Kalkanis A, Schepers C, Louvaris Z, Godinas L, Wauters E, Testelmans D, Lorent N, Van Mol P, Wauters J, De Wever W, Dooms C. Kalkanis A, et al. J Clin Med. 2022 May 11;11(10):2718. doi: 10.3390/jcm11102718. J Clin Med. 2022. PMID: 35628846 Free PMC article.
The primary endpoint was the correlation between global chest CTs score and global lung ultrasound score. ...We concluded that lung ultrasound is a reliable bedside clinical tool to assess global lung aeration in hospitalized non-critical …
The primary endpoint was the correlation between global chest CTs score and global lung ultrasound score. ...We conc …
Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform.
Morfouace M, Novello S, Stevovic A, Dooms C, Janžič U, Berghmans T, Dziadziuszko R, Gorlia T, Felip E, Paz-Ares L, Mazieres J, O'Brien M, Bironzo P, Vansteenkiste J, Lacroix L, Dingemans AC, Golfinopoulos V, Besse B. Morfouace M, et al. Sci Rep. 2022 May 18;12(1):8342. doi: 10.1038/s41598-022-12056-0. Sci Rep. 2022. PMID: 35585228 Free PMC article.
SPECTAlung was created in 2015 as a pan-European screening platform for patients with thoracic malignancies. ...Patients with thoracic malignancies at any stage of disease were recruited in SPECTAlung, from June 2015 to May 2019, in 7 different countries. Molecular …
SPECTAlung was created in 2015 as a pan-European screening platform for patients with thoracic malignancies. ...Patients with thoraci …
150 results